At Frontage, we simplify the effort of Investigational New Drug (IND) and reduce the risk by offering all of the critical IND-enabling services required to bring your lead candidate to Phase 1. By providing the right comprehensive end-to-end services, we can accelerate your IND program with the benefit of consistent quality, enhanced efficiency, and optimal cross-functional communications.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
In this podcast, we discuss 5 common errors in designing and managing IND-enabling toxicology programs with a special guest: Glenn Washer, EVP of Global Safety and Toxicology at Frontage Laboratories, Inc.
Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.
Critical reagents – the key components used in LBA – are central to ensuring the consistency and reliability of the assay and can often slow the progress of LBA due to limited availability. In this panel discussion, we examine the current scope of LBAs, the advantages and limitations including matrix interference, as well as the solutions for overcoming these. Additionally, we explore the platforms currently used and the key factors to consider when choosing a platform. Finally, we will highlight key areas for progression.